A LC-Electrospray tandem MS method for the analysis of naltrexone in canine plasma employing a molecular model to demonstrate the absence of internal standard deuterium isotope effects

被引:12
作者
Iyer, Sunil S.
Kellogg, Glen E.
Karnes, H. Thomas
机构
[1] Virginia Commonwealth Univ, Sch Pharm, Dept Pharmaceut, Richmond, VA 23298 USA
[2] Virginia Commonwealth Univ, Sch Pharm, Dept Med Chem, Richmond, VA 23298 USA
[3] Virginia Commonwealth Univ, Inst Struct Biol & Drug Discovery, Richmond, VA 23298 USA
关键词
D O I
10.1093/chromsci/45.10.694
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A simple and sensitive method is described for the determination of naltrexone (NAL), an opioid antagonist, in dog plasma. Sample processing involved a single step liquid-liquid extraction, followed by evaporation of the supernatant, and reconstitution of the residue prior to injection into the liquid chromatograph. The peak height ratio of NAL to [15,15,16-2H] naltrexone (NAL-d3) was used for quantitation. Observation of the chromatograms for NAL and NAL-d3 revealed that the mean retention times of the compounds were 1.32 and 1.31 min, respectively. The almost identical retention times possibly accounted for the absence of matrix effects influencing quantitation. Molecular mechanics calculations using SYBYL software were carried out to qualitatively and quantitatively assess analyte and isotopic internal standard stationary phase interactions. Binding energy values of -10.22 and -10.26 kcal/mole were obtained for NAL and NAL-d3, respectively. These data predict, semi-quantitatively, the absence of deuterium isotope effects that may influence quantitation. Calibration curves were linear from 10 pg/mL to 5014 pg/mL with a weighting factor of 1/x. Precision and accuracy and reverse predicted concentration residuals were within 15%. The method has been used successfully for the analysis of plasma samples from a pilot subcutaneous implantation study in dog.
引用
收藏
页码:694 / 700
页数:7
相关论文
共 24 条
[1]   Vivitrex®, an injectable, extended-release formulation of naltrexone, provides pharmacokinetic and pharmacodynamic evidence of efficacy for 1 month in rats [J].
Bartus, RT ;
Emerich, DF ;
Hotz, J ;
Blaustein, M ;
Dean, RL ;
Perdomo, B ;
Basile, AS .
NEUROPSYCHOPHARMACOLOGY, 2003, 28 (11) :1973-1982
[2]  
Bonfiglio R, 1999, RAPID COMMUN MASS SP, V13, P1175, DOI 10.1002/(SICI)1097-0231(19990630)13:12<1175::AID-RCM639>3.0.CO
[3]  
2-0
[4]  
Bugge CJL, 1996, DETERMINATION NALTRE
[5]   Quantification of naltrexone and 6,β-naltrexol in plasma and milk using gas chromatography-mass spectrometry -: Application to studies in the lactating sheep [J].
Chan, CF ;
Chiswell, GM ;
Bencini, R ;
Hackett, LP ;
Dusci, LJ ;
Ilett, KF .
JOURNAL OF CHROMATOGRAPHY B, 2001, 761 (01) :85-92
[6]   High-performance liquid chromatographic-tandem mass spectrometric evaluation and determination of stable isotope labeled analogs of rofecoxib in human plasma samples from oral bioavailability studies [J].
Chavez-Eng, CM ;
Constanzer, ML ;
Matuszewski, BK .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2002, 767 (01) :117-129
[7]   Depot naltrexone: long-lasting antagonism of the effects of heroin in humans [J].
Comer, SD ;
Collins, ED ;
Kleber, HD ;
Nuwayser, ES ;
Kerrigan, JH ;
Fischman, MW .
PSYCHOPHARMACOLOGY, 2002, 159 (04) :351-360
[8]   NALTREXONE - A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES AND THERAPEUTIC EFFICACY IN THE MANAGEMENT OF OPIOID DEPENDENCE [J].
GONZALEZ, JP ;
BROGDEN, RN .
DRUGS, 1988, 35 (03) :192-213
[9]  
Hurst WJ, 1999, PHARMAZIE, V54, P595
[10]   Evaluation of deuterium isotope effects in normal-phase LC-MS-MS separations using a molecular modeling approach [J].
Iyer, SS ;
Zhang, ZP ;
Kellogg, GE ;
Karnes, HT .
JOURNAL OF CHROMATOGRAPHIC SCIENCE, 2004, 42 (07) :383-387